Eli Lilly invests $3B to expand Wisconsin factory to help meet demand
for Mounjaro, Zepbound
Send a link to a friend
 [December 06, 2024]
Eli Lilly is spending another $3 billion to bulk up manufacturing
as the drugmaker seeks to stoke production of some blockbuster drugs and
future products.
Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory
it bought early this year, and the investment will help meet growing
demand for injectable products like its diabetes and obesity drugs,
Mounjaro and Zepbound.
Those drugs brought in a combined $4.4 billion in sales for Lilly in
this year’s third quarter.
The drugmaker plans to start construction of the expansion next year.
Lilly also announced other multibillion-dollar manufacturing expansion
projects near its Indianapolis headquarters earlier this year.
[to top of second column]
|
David Ricks, chair and CEO of Eli Lilly, fields a question during an
announcement of the company's $3 billion expansion in Wisconsin,
Thursday, Dec. 5, 2024, in Kenosha, Wis. (Sean Krajacic/The Kenosha
News via AP)
 Eli Lilly and Co. said Thursday that
it has slated more than $23 billion to construct, expand or acquire
manufacturing sites worldwide since 2020.
All contents © copyright 2024 Associated Press. All rights reserved |
